Targeted Cancer Therapies Market: Moving Towards a Brighter Future 2018-2026 By Top Players Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals
Standard chemotherapy agents are cytotoxic that kill tumor cells, while targeted therapies are often cytostatic that blocks tumor cell proliferation. Targeted therapies uses information about a person’s gene and protein to prevent, diagnose, and treat disease, which makes them extremely applicable in the making of precision medicine. Targeted therapy drugs are mainly used for the treatment of cancer, and are mostly used along with another treatments such as chemotherapy, surgery, and radiation therapy.
Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/931
Targeted cancer therapies market is growing due to the increasing incidences of cancers such as breast cancer, lung cancer, colorectal cancer, gastrointestinal cancer and among others. According to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in U.S. and 5,95,690 people died from the disease. However, increasing cancer research funding, rising insurance coverage and increase in number of new targeted anti-cancer drugs supports the revenue growth of targeted cancer therapies market.
National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research which include lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, ovarian cancer, uterine cancer, and cervical cancer. In addition, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.
Key Players in the Global Targeted Cancer Therapies Market
Some of the key players operating in the targeted cancer therapies market include Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals Inc., Pfizer, Inc., AVEO Pharmaceuticals Inc., and CYTOKINETICS INC.
Increased cost of therapy is a major constraint factor in the targeted cancer therapies market
According to the American Institute of Cancer Research (AICR), in U.S., cancer treatment costs more than any other disease, accounted for around US$ 895 billion a year. According to the study published in the Journal of Clinical Oncology, in 2015, targeted therapies accounted for 63% of the all chemotherapy expenditures in the U.S. in 2011. This further propels the targeted cancer therapies market in the near future. Targeted therapy drugs are very expensive, costs more than US$ 14,000 per patient in the initial stage of treatment. Various insurance companies cover the targeted therapy drugs that are taken orally according to the prescription.
Request Customization for Specific Details @ https://www.coherentmarketinsights.com/insight/request-customization/931
However, drugs that are given intravenously are covered in a different way by insurance plans, wherein patient end up paying more money. According to report published in the Journal of Clinical Oncology, in 2015, expenditure for cancer drugs has significantly increased to around US$ 200 for oral drugs per patient per month and around US$ 900 for targeted intravenous anti-cancer therapy per month. According to a study by US National Bureau of Economic Research, in 2015, prices of cancer drugs have increased 10% every year between 1995 and 2013. Rising cost of targeted oral anticancer medicines is a major factor in rising overall cost of targeted cancer therapies.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Targeted Cancer Therapies Market: Moving Towards a Brighter Future 2018-2026 By Top Players Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals here
News-ID: 1758145 • Views: 392
More Releases from Coherent Market Insights - Biotechnology
Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027." Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
More Releases for Targeted
Targeted Therapeutics: Technology and Market Dynamics
Targeted therapies are drugs or other substances that block the growth of unwanted cells and pathogens by interfering with specific molecules ("molecular targets") involved in the growth, progression, and spread of disease. Targeted therapies are sometimes called molecularly targeted drugs, molecularly targeted therapies, precision medicines, etc. The emerging field of target therapeutics offers varied potential treatments. Target therapies involves a wide range of therapies, such as, gene therapy, which uses
Medicinal Chemistry and Multi Targeted Drug Delivery
Medicinal Chemistry and Multi Targeted Drug Delivery" going to be held at San Francisco, USA during November 05-06, 2018 Dear Manager, We would like to solicit your gracious presence as a speaker at the upcoming Medicinal Chemistry and Multi Targeted Drug Delivery" going to be held at San Francisco, USA during November 05-06, 2018 The aim of this conference is to learn and share knowledge in Medicinal Chemistry and Multi Targeted Drug Delivery
B-Cell Maturation Antigen Targeted Therapies Market
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.
Cancer Targeted Therapy Market & Clinical Insight 2015
Cancer targeted therapy global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug
Cancer Targeted Therapy Market 2017 Development Trends
This report studies the global Cancer Targeted Therapy market, analyzes and researches the Cancer Targeted Therapy development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Advaxis Bind Therapeutics Boehringer Ingelheim Bristol Mayer Squibb Celldex Therapeutics Dendreon Corporation Eli Lily GalaxoSmithKline Galena Biopharma Genetech ImmunoCellular Therapeutics ImmunoGen Inovio Pharmaceuticals Johnson & Johnson NeoStem Oncology NewLink Genetics Northwest Biotherapeutics Merck Novartis Peregrine Pharmaceuticals Pfizer Roche Sanofi Seattle Genetics For more information about this report at http://www.reportsweb.com/global-cancer-targeted-therapy-market-size-status-and-forecast-2022 Market segment by Regions/Countries, this
Injectable Targeted Therapy Market
Targeted delivery is a clinical treatment used to deliver medication in patients to increase the concentration of medication in some parts of the body. Target specific drug delivery is localized, prolonged, targeted and have protected drug interaction with the diseased tissue. The advantage of injectable targeted therapy was the decrease in frequency of the dosages that are delivered to the patient, it more uniform effect of the drug, reduction of